CEBPB and neoplasm: In the realm of immunity, inhibiting glycolysis in breast cancer patients via the CEBPB pathway impedes G‐CSF and GM‐CSF production, reducing myeloid‐derived suppressor cells (MDSCs) and enhancing anti‐tumour immunity.39